|
GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
|
23 June 2022 |
|
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
|
02 June 2022 |
|
SK bioscience and GSK's adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study
|
29 April 2022 |
|
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
|
14 April 2022 |
|
GSK announces independent Consumer Healthcare company is to be called Haleon
|
22 February 2022 |
|
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
|
14 January 2022 |
|
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
|
14 December 2021 |
|
GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
|
03 December 2021 |
|
GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
|
01 December 2021 |
|
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
|
19 November 2021 |